Creyon , a trailblazer in AI/machine learning-driven engineering of oligonucleotide-based medicines (OBMs), is pleased to announce the appointment of two distinguished venture capitalists, Serge Messerlian and Shaquille Vayda, to its Board of Directors. Their extensive experience in life sciences and technology is expected to significantly contribute to Creyon’s mission of revolutionizing drug development.
- Appointments and Their Significance:
- Serge Messerlian, Operating Partner at DCVC Bio, and Shaquille Vayda, Principal at Lux Capital, join Creyon’s Board of Directors.
- Both bring a wealth of experience that aligns with Creyon’s goals in AI-enabled OBM engineering.
- Serge Messerlian’s Background and Contributions:
- Extensive leadership experience in life sciences, including roles at Teon Therapeutics and Janssen Oncology.
- Current roles include Operating Partner at DCVC Bio and board member at Auron Therapeutics and Plexium.
- Holds a B.S. in Physiology & Biotechnology, an M.S. in Molecular Genetics, and an MBA.
- Anticipates working with Creyon to shift industry standards in drug engineering.
- Shaquille Vayda’s Background and Contributions:
- Diverse experience in technology, aerospace, and life sciences with a focus on discovery platforms and data infrastructure.
- Current Principal at Lux Capital and board member at several companies including Enveda Biosciences and LabGenius.
- Previous experience includes roles at Parthenon, Illumina, NASA, and Northrop Grumman.
- Holds a B.S. in Mechanical Engineering and is passionate about integrating technology with natural sciences.
- Creyon Bio’s Growth and Future Prospects:
- The company is at a pivotal stage of growth and innovation in oligonucleotide-based medicine.
- Serge and Shaquille’s appointments are expected to enhance Creyon’s capabilities and drive advancements in drug engineering and delivery systems.
The appointment of Serge Messerlian and Shaquille Vayda to Creyon Bio’s Board of Directors marks a significant milestone for the company. Their expertise in life sciences, technology, and venture capital will be instrumental in advancing Creyon’s pioneering platform for oligonucleotide-based medicines. With their strategic guidance, Creyon is well-positioned to transform the future of drug development and delivery.
